학술논문

GFPC 06-2018: A multicenter non-randomized phase II study evaluating platinum-pemetrexed-atezolizumab ( plus /-bevacizumab) for patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutations, ALK rearrangement or ROS1 fusion progressing after targeted therapies
Document Type
Journal
Source
ANNALS OF ONCOLOGY; SEP 2020, 31 pS892-pS892, 1p. Supplement: 4
Subject
Language
English
ISSN
15698041